AIM: Angiogenesis correlates with disease progression in various haematological malignancies. This study investigated the association between microvascular density (MVD) and the Ki-67 proliferation index (Ki-67 PI), bone marrow infiltration, and C reactive protein (CRP) in patients with multiple myeloma. METHODS: Bone marrow MVD was examined in 44 biopsies at diagnosis and 15 in plateau phase by immunostaining the endothelial cells with a monoclonal antibody to CD34. The Ki-67 PI was evaluated by a double immunostaining technique using the monoclonal antibodies MIB-1 and CD38. RESULTS: MVD, Ki-67 PI, bone marrow infiltration, and CRP were significantly higher in pretreatment patients than in controls and decreased in patients achieving plateau phase. MVD significantly correlated with Ki-67 PI and infiltration, and Ki-67 correlated with infiltration. CONCLUSION: In multiple myeloma, apart from being a marker of proliferative activity, Ki-67 is also associated with bone marrow angiogenesis and tumour burden.
AIM: Angiogenesis correlates with disease progression in various haematological malignancies. This study investigated the association between microvascular density (MVD) and the Ki-67 proliferation index (Ki-67 PI), bone marrow infiltration, and C reactive protein (CRP) in patients with multiple myeloma. METHODS: Bone marrow MVD was examined in 44 biopsies at diagnosis and 15 in plateau phase by immunostaining the endothelial cells with a monoclonal antibody to CD34. The Ki-67 PI was evaluated by a double immunostaining technique using the monoclonal antibodies MIB-1 and CD38. RESULTS: MVD, Ki-67 PI, bone marrow infiltration, and CRP were significantly higher in pretreatment patients than in controls and decreased in patients achieving plateau phase. MVD significantly correlated with Ki-67 PI and infiltration, and Ki-67 correlated with infiltration. CONCLUSION: In multiple myeloma, apart from being a marker of proliferative activity, Ki-67 is also associated with bone marrow angiogenesis and tumour burden.
Authors: R Chaudhary; M Bromley; N W Clarke; C D Betts; R J Barnard; W D Ryder; S Kumar Journal: Anticancer Res Date: 1999 Jul-Aug Impact factor: 2.480
Authors: S V Rajkumar; T Leong; P C Roche; R Fonseca; A Dispenzieri; M Q Lacy; J A Lust; T E Witzig; R A Kyle; M A Gertz; P R Greipp Journal: Clin Cancer Res Date: 2000-08 Impact factor: 12.531
Authors: S Singhal; J Mehta; R Desikan; D Ayers; P Roberson; P Eddlemon; N Munshi; E Anaissie; C Wilson; M Dhodapkar; J Zeddis; B Barlogie Journal: N Engl J Med Date: 1999-11-18 Impact factor: 91.245
Authors: W H Goodson; D H Moore; B M Ljung; K Chew; B Mayall; H S Smith; F M Waldman Journal: Breast Cancer Res Treat Date: 2000-01 Impact factor: 4.872
Authors: T Padró; S Ruiz; R Bieker; H Bürger; M Steins; J Kienast; T Büchner; W E Berdel; R M Mesters Journal: Blood Date: 2000-04-15 Impact factor: 22.113
Authors: S Vincent Rajkumar; Ruben A Mesa; Rafael Fonseca; Georgene Schroeder; Matthew F Plevak; Angela Dispenzieri; Martha Q Lacy; John A Lust; Thomas E Witzig; Morie A Gertz; Robert A Kyle; Stephen J Russell; Philip R Greipp Journal: Clin Cancer Res Date: 2002-07 Impact factor: 12.531
Authors: Pavla Veselá; Zbyněk Tonar; David Sálek; Samuel Vokurka; Marek Trněný; Roman Kodet; Mojmír Moulis; Petra Kašparová; Zdeňka Vernerová; Zuzana Velenská; Jan Stříteský; Michal Michal; Ludmila Boudová Journal: Virchows Arch Date: 2014-07-22 Impact factor: 4.064
Authors: Michael G Alexandrakis; Ioannis K Neonakis; Constantina A Pappa; Ioannis Konsolas; Maria Kokonozaki; Rodanthi Vyzoukaki; Stella Soundoulounaki; Athina Xekalou; Katerina Sfiridaki; George Tsirakis Journal: J Cancer Res Clin Oncol Date: 2015-03-13 Impact factor: 4.553
Authors: George Tsirakis; Constantina A Pappa; Maria Kaparou; Anna Boula; Vaitsa Katsomitrou; Athina Xekalou; Stavroula Kyriakaki; Michael G Alexandrakis Journal: Tumour Biol Date: 2012-12-16
Authors: Olivera Marković; D Marisavljević; V Cemerikić; A Vidović; M Perunicić; M Todorović; I Elezović; M Colović Journal: Med Oncol Date: 2008-05-01 Impact factor: 3.064